| Trial ID: | L0141 |
| Source ID: | NCT02637973
|
| Associated Drug: |
Empagliflozin
|
| Title: |
Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
|
| Acronym: |
EmLiFa
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Type 2 Diabetes|Non-alcoholic Fatty Liver Disease
|
| Interventions: |
Drug: Empagliflozin|Drug: Placebo
|
| Outcome Measures: |
Change in liver fat content
|
| Sponsor/Collaborators: |
The Deutsche Diabetes Forschungsgesellschaft e.V.|Boehringer Ingelheim|German Diabetes Center
|
| Gender: |
All
|
| Age: |
18 Years to 75 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 4
|
| Enrollment: |
84
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
December 2015
|
| Completion Date: |
August 2018
|
| Results First Posted: |
--
|
| Last Update Posted: |
January 14, 2019
|
| Locations: |
Charite Universitaetsmedizin Berlin, Berlin, Germany|Universit??tsklinikum Carl Gustav Carus an der Technischen Universit??t Dresden, Dresden, Germany|German Diabetes Center, Dusseldorf, Germany|University Clinic Heidelberg, Heidelberg, Germany|University Clinic T??bingen, T??bingen, Germany
|
| URL: |
https://ClinicalTrials.gov/show/NCT02637973
|
